Neotrofin leteprinim: NEOT began a U.S. double-blind, placebo-controlled Phase II trial of Neotrofin, given at a 1,000 mg dose twice daily, in 50 patients with

NeoTherapeutics Inc. (NEOT), Irvine, Calif. Product: Neotrofin leteprinim (AIT-082) Business: Neurological Therapeutic category: Growth factor, Nerve regeneration Target: Neurotrophic factors Descript...